FATMA AHMOUDA: Open Payments
NPI 1982311718 · FULTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,492 in 178 payments from 13 companies in 2025. Trend: 2023 $154 · 2024 $842 · 2025 $2,492
Food & beverage: $2,461Education: $31
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $392 |
| Alkermes, Inc. | 36 | $336 |
| Vanda Pharmaceuticals Inc. | 12 | $296 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $296 |
| Otsuka America Pharmaceutical, Inc. | 12 | $185 |
| Janssen Pharmaceuticals, Inc | 13 | $182 |
| Teva Pharmaceuticals USA, Inc. | 10 | $164 |
| Axsome Therapeutics, Inc. | 7 | $162 |
| ABBVIE INC. | 11 | $160 |
| Supernus Pharmaceuticals, Inc. | 9 | $147 |
Products named: INGREZZA, ARISTADA, FANAPT, CAPLYTA, INVEGA SUSTENNA, Auvelity, REXULTI, VRAYLAR.
Industry payments across MO — which companies pay providers there.
